Elizabeth Crowley Sells 15,000 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stock

Celldex Therapeutics, Inc. (NASDAQ:CLDX) VP Elizabeth Crowley sold 15,000 shares of the company’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $35.06, for a total value of $525,900.00. Following the completion of the sale, the vice president now directly owns 9,074 shares of the company’s stock, valued at $318,134.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Elizabeth Crowley also recently made the following trade(s):

• On Thursday, May 30th, Elizabeth Crowley sold 38,597 shares of Celldex Therapeutics stock. The shares were sold at an average price of $33.64, for a total value of $1,298,403.08.

Celldex Therapeutics Stock Up 1.2 %

NASDAQ CLDX opened at $36.01 on Thursday. The stock has a market capitalization of $2.37 billion, a P/E ratio of -12.64 and a beta of 1.47. Celldex Therapeutics, Inc. has a 52-week low of $22.11 and a 52-week high of $53.18. The firm has a 50-day moving average price of $37.92 and a 200 day moving average price of $38.84.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $1.30 million. On average, equities research analysts expect that Celldex Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CLDX. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research report on Monday, June 3rd. Guggenheim increased their target price on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Wolfe Research started coverage on Celldex Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $51.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Friday, March 22nd. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $63.00.

Institutional Investors Weigh In On Celldex Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its holdings in shares of Celldex Therapeutics by 48.9% in the 4th quarter. BNP Paribas Financial Markets now owns 136,601 shares of the biopharmaceutical company’s stock valued at $5,418,000 after purchasing an additional 44,878 shares in the last quarter. Wellington Management Group LLP increased its holdings in Celldex Therapeutics by 5.9% in the third quarter. Wellington Management Group LLP now owns 5,431,833 shares of the biopharmaceutical company’s stock valued at $149,484,000 after buying an additional 300,406 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Celldex Therapeutics by 105.3% during the 4th quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock valued at $109,308,000 after acquiring an additional 1,413,722 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Celldex Therapeutics by 13.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 409,391 shares of the biopharmaceutical company’s stock worth $16,236,000 after acquiring an additional 47,844 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its holdings in shares of Celldex Therapeutics by 166.7% in the 4th quarter. Affinity Asset Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $15,864,000 after acquiring an additional 250,000 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.